沪市主板医药股首季业绩稳中略升，龙头企业提供“强支撑”

21世纪经济报道05-08 21:44

一季报落幕，沪市一批医药龙头企业首季展现出的业绩也提振人心。　　数据显示，沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元，同比小幅上升2%，合计实现净利润247亿元，同比上升0.5%。其中，药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润，两公司均实现了一季度营收、净利润的显著增长，为整个行业首季表现提供了强力支撑。　　在行业整体仍面临控费压力、创新药...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2633452589?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-08 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633452589","market":"us","top_or_hot":-1,"title":"沪市主板医药股首季业绩稳中略升，龙头企业提供“强支撑”","media":"21世纪经济报道","content":"<div>\n<p>一季报落幕，沪市一批医药龙头企业首季展现出的业绩也提振人心。　　数据显示，沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元，同比小幅上升2%，合计实现净利润247亿元，同比上升0.5%。其中，药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润，两公司均实现了一季度营收、净利润的显著增长，为整个行业首季表现提供了强力支撑。　　在行业整体仍面临控费压力、创新药...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605083731825533.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>沪市主板医药股首季业绩稳中略升，龙头企业提供“强支撑”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n沪市主板医药股首季业绩稳中略升，龙头企业提供“强支撑”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-08 21:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202605083731825533.html><strong>21世纪经济报道</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一季报落幕，沪市一批医药龙头企业首季展现出的业绩也提振人心。　　数据显示，沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元，同比小幅上升2%，合计实现净利润247亿元，同比上升0.5%。其中，药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润，两公司均实现了一季度营收、净利润的显著增长，为整个行业首季表现提供了强力支撑。　　在行业整体仍面临控费压力、创新药...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605083731825533.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605083731825533.html","article_id":"2633452589","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083731825533.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633452589","pubTimestamp":1778247892,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"一季报落幕，沪市一批医药龙头企业首季展现出的业绩也提振人心。数据显示，沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元，同比小幅上升2%，合计实现净利润247亿元，同比上升0.5%。其中，药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润，两公司均实现了一季度营收、净利润的显著增长，为整个行业首季表现提供了强力支撑。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1161":"生物科技","09939":"开拓药业-B","BK1574":"生物医药B类股"},"translate_title":"The first quarter performance of pharmaceutical stocks on the main board of Shanghai Stock Exchange rose slightly steadily, and leading companies provided \"strong support\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"09939":1.5},"content_text":"一季报落幕，沪市一批医药龙头企业首季展现出的业绩也提振人心。　　数据显示，沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元，同比小幅上升2%，合计实现净利润247亿元，同比上升0.5%。其中，药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润，两公司均实现了一季度营收、净利润的显著增长，为整个行业首季表现提供了强力支撑。　　在行业整体仍面临控费压力、创新药同质化竞争加剧的背景下，恒瑞医药2026年一季报展现出强劲的增长韧性。报告期内，公司实现营业收入81.41亿元，同比增长12.98%，归母净利润22.82亿元，同比大幅增长21.78%，利润增速继续显著跑赢收入增速。核心亮点在于创新药销售收入达45.26亿元，同比增长25.75%，占药品销售收入比重历史性突破至61.69%，成为业绩增长的核心引擎。　　同时，公司国际化布局持续兑现，BD对外许可业务确认收入7.87亿元，且“NewCo”模式合作伙伴Kailera成功登陆纳斯达克，标志着公司全球化创新合作路径取得里程碑式突破。在持续高强度研发投入的支撑下，公司正加速形成“创新药放量”与“全球价值兑现”双轮驱动的高质量增长格局。　　CXO领域龙头药明康德2026年一季度业绩强劲增长，首次实现单季度营收突破百亿元，达到124.4亿元（同比+28.8%）；经调整non-IFRS归母净利润达到46亿元（同比+71.7%），利润增速超过营收增速，毛利率、净利率也纷纷创下新高，彰显经营质量，验证了CRDMO一体化龙头的盈利修复能力；一季度，药明康德持续经营业务在手订单597.7亿元（同比+23.6%），为达成全年指引（513亿~530亿元）注入信心。　　而从一季度业绩来看，CXO行业增长逻辑已从传统小分子向ADC、多肽/寡核苷酸（GLP-1相关）、细胞与基因治疗（CGT）等新分子类型重构，这类业务毛利率普遍高于传统业务，推动行业盈利中枢抬升，药明康德TIDES（寡核苷酸和多肽）业务一季度收入达23.8亿元，预计全年将实现40%以上高速增长。（文章来源：21世纪经济报道）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633452589","isCrawlerRequest":true}